Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 6 (June)

1. The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line.
   Leuk Res, 29(7): 793-802. [Abstract] [Full-text]
2. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
   Clin Cancer Res, 11(11): 4182-90. [Abstract] [Full-text]
3. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
   Cancer Res, 65(11): 4500-5. [Abstract] [Full-text]
4. Eosinophilic pneumonias.
   Allergy, 60(7): 841-57. [Abstract] [Full-text]
5. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
   Blood, 105(12): 4849-52. [Abstract] [Full-text]
6. Metastatic malignant melanoma presenting as pancytopenia in a three-year-old boy.
   Pediatr Blood Cancer, 45(1): 60-3. [Abstract] [Full-text]
7. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
   Prostate, 63(4): 385-94. [Abstract] [Full-text]
8. Recent studies in novel therapy for metastatic sarcomas.
   Hematol Oncol Clin North Am, 19(3): 573-90, viii. [Abstract] [Full-text]
9. Gastrointestinal stromal tumors.
   Hematol Oncol Clin North Am, 19(3): 547-64, vii. [Abstract] [Full-text]
10. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
    Structure (Camb), 13(6): 861-71. [Abstract] [Full-text]
11. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis.
    Am J Respir Crit Care Med, 171(12): 1421-9. [Abstract] [Full-text]
12. Rapid computational identification of the targets of protein kinase inhibitors.
    J Med Chem, 48(12): 4138-52. [Abstract] [Full-text]
13. Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis.
    J Gastroenterol Hepatol, 20(6): 818-24. [Abstract] [Full-text]
14. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
    J Clin Oncol, 23(17): 3948-56. [Abstract] [Full-text]
15. A functional approach to questions about life, death, and phosphorylation.
    Cancer Cell, 7(6): 503-4. [Abstract] [Full-text]
16. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
    Cancer Genet Cytogenet, 160(1): 22-6. [Abstract] [Full-text]
17. Effect of Tyrosine Kinase Inhibition Using Imatinib on Normal Lymphohematopoietic Cells.
    Ann N Y Acad Sci, 1044: 168-177. [Abstract] [Full-text]
18. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
    Clin Cancer Res, 11(12): 4460-8. [Abstract] [Full-text]
19. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case.
    Dis Colon Rectum, 48(6): 1316-9. [Abstract] [Full-text]
20. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    J Clin Oncol, 23(18): 4100-9. [Abstract] [Full-text]
21. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines.
    Exp Hematol, 33(7): 767-75. [Abstract] [Full-text]
22. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Blood Rev, 19(5): 243-52. [Abstract] [Full-text]
23. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
    Br J Clin Pharmacol, 60(1): 35-44. [Abstract] [Full-text]
24. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens.
    Cancer, 105(3): 165-70. [Abstract] [Full-text]
25. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven.
    Clin Sci (Lond), 109(1): 13-25. [Abstract] [Full-text]
26. Gastrointestinal stromal tumors: CT and MRI findings.
    Eur Radiol, 15(7): 1407-14. [Abstract] [Full-text]
27. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
    Blood, 106(1): 227-34. [Abstract] [Full-text]
28. Gastrointestinal stromal tumour treated with neoadjuvant imatinib.
    J Clin Pathol, 58(7): 779-81. [Abstract] [Full-text]
29. No GIST-type c-kit gain of function mutations in neuroblastic tumours.
    J Clin Pathol, 58(7): 762-5. [Abstract] [Full-text]
30. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.
    Leuk Res, 29(8): 971-3. [Abstract] [Full-text]
31. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    PLoS Med, 2(3): e73. [Abstract] [Full-text]
32. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
    Histopathology, 47(1): 41-7. [Abstract] [Full-text]
33. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas.
    Jpn J Clin Oncol, 35(6): 338-41. [Abstract] [Full-text]
34. Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate.
    Pediatr Blood Cancer, 45(2): 202-6. [Abstract] [Full-text]
35. Dynamics of chronic myeloid leukaemia.
    Nature, 435(7046): 1267-70. [Abstract] [Full-text]
36. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
    Transfusion, 45(7): 1214-20. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.